Lantheus 3Q 2026: Revenue $389.91M, EPS $0.33 — 10-Q Summary

Lantheus reported Q3 2026 revenue of $389.91M, up 1.5% YoY, driven by Neuraceq, PYLARIFY, and DEFINITY sales. Net income fell 19.4% to $22.37M due to higher R&D costs. FDA approved TAUKLARIFY and BRAVNETSA, with LNTH-2501 receiving a Complete Response Letter.

Original reporting

tradingview.com

Published Nov 5, 2026, 1:01 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Nov 5, 2026, 1:09 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Lantheus 3Q 2026: Revenue $389.91M, EPS $0.33 — 10-Q Summary — source image — Source · tradingview.com

Decision brief

The 30-second read

$LNTHBullishMed

Why it matters

Earnings miss may trigger short‑term price pressure, but upcoming product launches could offset.

Market read

First report of Q3 numbers; investors will reassess earnings expectations and pipeline outlook.

What to watch

The Complete Response Letter for LNTH-2501 may pose a risk to future pipeline valuation.

Relevance 8/10Novelty 8/10Timing: post-market release

Background

Lantheus Holdings (LNTH) filed its Form 10‑Q for Q3 2026, providing detailed financial and product updates.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$LNTHBullishHigh confidence

Context

Lantheus Holdings reported Q3 2026 results with revenue $389.9M, EPS $0.33 and a 19.5% earnings decline.

Expected impact

potential downside as the market prices in the earnings decline and higher R&D costs.

Evidence & confidence

First disclosure of quarterly numbers; EPS fell 19.5% YoY, likely prompting short‑term sell pressure.

Market effects

Sector

Highlights mixed performance in the nuclear imaging and radiopharmaceutical sector.

Regional

US biotech/healthcare sector may see modest pullback.

Global

Limited to investors tracking US-listed biotech earnings.

Counterpoint

What could challenge this read

Despite earnings miss, the FDA approvals for TAUKLARIFY and BRAVNETSA could drive longer‑term upside.

Key entities

company
Lantheus Holdings, Inc.
US‑listed biotech company reporting Q3 2026 results.

Read at source ← All news

$LNTHMedAI 8/10

Lantheus to Sell CDMO Business and Springfield Facility to PharmaLogic

Lantheus agreed to sell its CDMO business and a New Jersey facility to PharmaLogic. The deal is subject to closing conditions and includes a long-term supply agreement for lutetium Lu 177 dotatate. Lantheus will provide transition services post-closing, according to an SEC filing.

tradingview.comNov 10

$LNTHMed

Lantheus Holdings, Inc., a Delaware corporation, entered into a definitive agreement with PharmaLogic Holdings Corp. to sell its contract development and…

Lantheus Holdings, Inc. (LNTH) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On November 8, 2026, Lantheus Holdings, Inc., a Delaware corporation (“Lantheus” or the “Company”), entered into a definitive agreement with PharmaLogic Holdings Corp. (“PharmaLogic”) to sell its contract development and manufacturing organization (“CDMO”)

SEC EDGAR 8-KNov 9

Med

PharmaLogic Holdings Corp. to Acquire Lantheus CDMO Business

PharmaLogic Holdings Corp. will acquire Lantheus' CDMO business and a New Jersey facility. The deal includes a long-term supply agreement for lutetium Lu 177 dotatate. Financial terms were not disclosed, and the transaction is subject to regulatory approval.

tradingview.comNov 9

$LNTHMedAI 8/10

PharmaLogic to Acquire Lantheus' CDMO Business and Springfield, New Jersey Manufacturing Facility

PharmaLogic Holdings Corp. agreed to acquire Lantheus' CDMO business and Springfield, NJ facility. The deal expands PharmaLogic's U.S. radiopharmaceutical manufacturing capacity and creates a transatlantic CDMO platform. Lantheus will receive a long-term supply agreement for lutetium Lu 177 dotatate. The transaction is subject to regulatory approval and customary closing conditions.

prnewswire.comNov 9

$LNTHMed

Lantheus Holdings Inc earnings beat by $0.42, revenue topped estimates

Lantheus Holdings Inc (LNTH) reported Q3 EPS of $1.68, beating estimates by $0.42, with revenue of $389.9M, exceeding expectations. The stock is up 88.38% over the past year. According to InvestingPro, the company's financial health is rated as 'great performance'.

investing.comNov 5

$LNTHHigh

Lantheus Q3 Revenue Rises 1.5%; Adjusted EPS Reaches $1.68

Lantheus reported Q3 2026 revenue of $389.9M, up 1.5% YoY, with adjusted EPS at $1.68. The company received FDA approvals for TAUKLARIFY and BRAVNETSA. Lantheus suspended 2026 guidance due to its pending merger with Curium at $102.50 per share plus potential CVRs.

tradingview.comNov 5